Figures & data
Figure 1. CYP2C19*2 genotypes and influence of *2 allele carriage on prasugrel treatment: (A) CYP2C19*2 genotype frequency in the cohort without (in blue) vs. with (in red) treatment adjustment (p-value was calculated across genotypes) and (B) platelet aggregation measurements following prasugrel LD for patients without (n = 70) and with (n = 54) CYP2C19*2 carriage. Notes: The blue lines represent median values per group. Red dots denote individual platelet aggregation measurements after prasugrel LD administration. The dotted line in black denotes the HCPR consensus cut-off value (≥468 AU·min). ADP, adenosine diphosphate; AU, aggregation units; LD, loading dose; wt, wild type.
